The decrease in cancellous bone formation after estrogen treatment is generally thought to be coupled with a prior decrease in bone resorption. To test the possibility that estrogen has rapid tissue-specific actions on bone metabolism, we determined the time course (1-32 h) effects of diethylstilbestrol on steady-state mRNA levels for immediate-response genes, extracellular matrix proteins, and signaling peptides in the proximal tibial metaphysis and uterus by using Northern blot and RNase protection assays. The regulation of signaling peptides by estrogen, although tissue specific, followed a similar time course in bone and uterus. The observed rapid decreases in expression of insulin-like growth factor I, a growth factor associated with bone formation; decreases in mRNA levels for bone matrix proteins; evidence for reduced bone matrix synthesis; failure to detect rapid increases in mRNA levels for signaling peptides implicated in mediating the inhibitory effects of estrogen on bone resorption (interleukin-1 and -6) as well as other cytokines that can increase bone resorption; and the comparatively long duration of the bone remodeling cycle in rats indicate that estrogen can decrease bone formation by a mechanism that does not require a prior reduction in bone resorption.

mRNA levels; estrogen receptors; cytokines; growth factors; matrix proteins; bone formation

This article has been cited by other articles:

				R. C. Poulsen, P. J. Moughan, and M. C. Kruger Docosahexaenoic Acid and 17{beta}-Estradiol Co-Treatment Is More Effective Than 17{beta}-Estradiol Alone in Maintaining Bone Post-Ovariectomy Experimental Biology and Medicine, May 1, 2008; 233(5): 592 - 602. [Abstract] [Full Text] [PDF]